Line 30: |
Line 30: |
| |- | | |- |
| |'''Inflammatory''' | | |'''Inflammatory''' |
− | |[[Acute Gastritis - WikiClinical|Gastritis]] | + | |[[Acute Gastritis - WikiClinical|Gastritis]], [[Pancreatitis - WikiClinical|Pancreatitis]] |
| |- | | |- |
| |'''Neoplastic''' | | |'''Neoplastic''' |
− | |Adenocarcinoma, lymphosarcoma, leiomyoma | + | |Adenocarcinoma, lymphosarcoma, leiomyoma, gastrinoma (Zollinger-Ellison syndrome), |
| |- | | |- |
| |'''Metabolic/endocrine''' | | |'''Metabolic/endocrine''' |
Line 91: |
Line 91: |
| | | |
| ==Treatment== | | ==Treatment== |
− | The main aim is to treat any primary underlying cause whilst giving general support. This may be hydrating, restoring electrolytes and acid-base and also helping the gastric lining to recover. | + | The main aim is to treat any primary underlying cause whilst giving general support. This may be hydrating, restoring electrolytes and acid-base and also helping the gastric lining to recover. Anti-ulcerative therapy should be continued for up to 6-8 weeks. |
| | | |
| ===[[Fluid Therapy]]=== | | ===[[Fluid Therapy]]=== |
Line 102: |
Line 102: |
| *Blocking of acid secretion: | | *Blocking of acid secretion: |
| **[[Gastroprotective Drugs#Histamine (H2) Receptor Antagonists|Histamine receptor antagonists]]: | | **[[Gastroprotective Drugs#Histamine (H2) Receptor Antagonists|Histamine receptor antagonists]]: |
− | ***cimetidine | + | ***cimetidine (10 mg/kg, per os (PO)/intramuscular (IM)/intravenous (IV), three times daily (tid) |
− | ***ranitidine | + | ***ranitidine (Dogs: 2 mg/kg, PO/IV, tid. Cats: 2.5 mg/kg, IV two times daily (bid) or 3.5 mg/kg, PO bid |
− | ***famotidine | + | ***famotidine (0.5-1 mg/kg, PO/IV, once daily (sid)-bid |
| **Gastrin antagonists: | | **Gastrin antagonists: |
| ***proglumide | | ***proglumide |
Line 111: |
Line 111: |
| ***pirenzepine | | ***pirenzepine |
| **Adenyl cyclase inhibitors: | | **Adenyl cyclase inhibitors: |
− | ***[[Gastroprotective Drugs#Prostaglandin E Analogues|prostaglangin E2 (PGE) analogues]] (misoprostol) | + | ***[[Gastroprotective Drugs#Prostaglandin E Analogues|prostaglangin E2 (PGE) analogues]] (misoprostol (Dogs: 2-5µg/kg PO tid) |
| **[[Gastroprotective Drugs#Proton Pump Inhibitors|H<sup>+</sup>:K<sup>+</sup>ATPase inhibitors ]]:- for use when patient is refractory to histamine antagonists | | **[[Gastroprotective Drugs#Proton Pump Inhibitors|H<sup>+</sup>:K<sup>+</sup>ATPase inhibitors ]]:- for use when patient is refractory to histamine antagonists |
− | ***omeprazole - good for exercise induced gastric ulceration | + | ***omeprazole (0.7 mg/kg PO sid) - good for exercise induced gastric ulceration |
| | | |
| ===Mucosal protectants=== | | ===Mucosal protectants=== |
− | Such as misoprostol can be given alongside [[NSAIDs|NSAIDs]] to decrease the risk of ulceration. '''[[Gastroprotective Drugs#Binding Agents|Sucralfate]]''', which is polyaluminium sucrose sulphate, binds to damaged mucosa and assists in the treatment of gastric ulceration. It is best given 2 hours after acid inhibitors to prevent interference. | + | Such as misoprostol can be given alongside [[NSAIDs|NSAIDs]] to decrease the risk of ulceration. '''[[Gastroprotective Drugs#Binding Agents|Sucralfate]]''' (Dogs: 0.5-1g PO bid/tid. Cats: 0.25g PO bid/tid) which is polyaluminium sucrose sulphate, binds to damaged mucosa and assists in the treatment of gastric ulceration. It is best given 2 hours after acid inhibitors to prevent interference. |
| | | |
| ===Prophylaxis=== | | ===Prophylaxis=== |
Line 134: |
Line 134: |
| | | |
| ==Prognosis== | | ==Prognosis== |
− | Depends upon the cause
| + | For animals with peptic ulcers is good. Prognosis is poorer for patients with renal or hepatic failure related ulcers. It is also poor for animals with gastric carcinoma and gastrinoma. |
| | | |
| ==References== | | ==References== |
| | | |
| Hall, J.E., Simpson, J.W. and Williams, D.A., (2005) '''BSAVA Manual of Canine and Feline Gastroenterology (2nd Edition)''' ''BSAVA'' | | Hall, J.E., Simpson, J.W. and Williams, D.A., (2005) '''BSAVA Manual of Canine and Feline Gastroenterology (2nd Edition)''' ''BSAVA'' |
| + | |
| + | Merck & Co (2008) '''The Merck Veterinary Manual''' |